Investor Relations

Investment Case

The discovery of the significance of RNA activity in cell protein production is one of the most important medical breakthroughs in recent years. Silence Therapeutics has developed its own RNA technology, along with proprietary delivery systems. Combined, these enable the development of therapeutics for diseases with high unmet medical need.

Silence is one of very few listed companies with the ability to modulate gene expression both up and down, in vivo.

The RNA technology field has high barriers to entry, with much investment and know-how required to develop RNA drugs to this stage. Our technology is already in the clinic and has been used in Phase 2 trials.  We also have a robust IP estate defending our proprietary technology.

Our proprietary gene silencing module can be designed to regulate expression of potentially any gene, and our delivery systems need no immune suppressants.  Effective delivery capability will be key for the next stage in genetic medicine, targeting disease right at the cause.

Silence has an expanding early stage pipeline and an embedded algorithm for cost effective pre-clinical drug development with clear go/no-go milestones.  We take pride in our research collaborations with world leading research institutions such as Oxford University, Cambridge University and Imperial College London, to develop the most promising drug candidates.

Stock Information

Free float, as defined by the AIM Rules, is 56.06% of the current issued share capital.

Shareholder Number of shares Percentage of share capital
Richard Griffiths               15,299,306 21.92%
Robert Keith*               12,085,371 17.31%
Invesco Limited                8,333,333 11.94%
Henderson Global Investors                5,072,593 7.27%
Aviva plc                4,392,771 6.29%
Woodford Investment Management LLP                4,166,666 5.97%
Sarossa plc                2,189,467 3.14%
Ali Mortazavi                1,937,399 2.78%

*total holding 12,085,371 including indirect holdings

Last updated: September 2016

Number of securities in issue: 69,801,624 ordinary shares

Changes in share price:

Last 30 days Last 4 years
Share Price (last 30 days) Share Price (last 4 years)

Shareholder information and documents

Notice of Annual General Meeting 17 June 2016
Proxy Forms for Annual General Meeting 17 June 2016

Constitutional documents

Most Recent AIM Admission Document
Summary of Articles
Memorandum of Association
Full Articles of Association

Registered address:

27-28 Eastcastle Street
+44 (0)20 299 2058

Key advisers

Nominated adviser and joint broker:

Canaccord Genuity Limited
88 Wood Street
+44 (0)20 7523 8321

Joint broker:

Peel Hunt LLP
Moor House
120 London Wall
+44 (0)20 7418 8900

Legal adviser:

Covington & Burling LLP
265 Strand
+44 (0)20 7067 2000


PricewaterhouseCoopers LLP
Abacus House
Castle Park
+44 (0)1223 460055


Capita IRG plc
Northern House
Woodsome Park
Fenay Bridge
+44 (0)871 664 0300

Investor enquiries:
+44 20 3700 9711

Corporate Governance

Silence Therapeutics has not adopted a code on corporate governance but takes corporate governance very seriously and is currently working towards compliance with a formal UK code. The Company’s existing corporate governance arrangements are set out below.

Policy and strategy

The Board of Directors is responsible for approving the Company’s policy and strategy. It meets on a regular basis and has a schedule of matters specifically reserved for it to consider. The executive management team supply the Board with appropriate and timely information and the Directors are free to seek any further information they consider necessary. All Directors have access to regular training and independent professional advice at the Company’s expense.

Internal controls

The Board is responsible for maintaining a strong system of internal controls to safeguard shareholders’ investment and the Company’s assets and for reviewing its effectiveness. The system of internal financial control is designed to provide reasonable, but not absolute, assurance against material misstatement or loss.

An audit committee has been established and comprises three non-executive directors. The Committee is responsible for ensuring that the financial performance of the Group is properly monitored and reported on, as well as meeting the Company’s auditor and reviewing any reports from the auditor regarding accounts and internal control systems.

Board Committees

Remuneration Committee

The Remuneration Committee assists the board in the discharging of its responsibilities related to remuneration of the Company’s executive officers

Chairman: Andy Richards

Members: Stephen Parker, Alistair Gray

Audit Committee

The Audit Committee assists the board’s oversight of accounting and financial reporting processes and the audits of the Company’s financial statements

Chairman: Alistair Gray

Members: Stephen Parker, Andy Richards

Nominations Committee

The Nominations Committee recommends to the board those persons to be nominated for election as directors at any shareholders meeting

Chairman: Stephen Parker

Members: Alistair Gray, Andy Richards

Relations with shareholders

Silence Therapeutics values the views of its shareholders and recognises their interest in the Company’s strategy and performance. The Annual General Meeting is used to communicate with private investors and they are encouraged to participate.